PharmaCielo to Participate in 2020 Cowen Boston Cannabis Conference
TORONTO, Canada (November 13, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it will be participating in Cowen’s 2020 Boston Cannabis Conference, to be held virtually between November 30 and December 2, 2020.
The Company’s CEO David Attard will participate in one-on-one meetings.
For more information regarding registering for the 2020 Cowen Boston Cannabis Conference please visit: Cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre located in Rionegro, Colombia.
The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
For further information:
David Gordon, Chief Corporate Officer
International: Gal Wilder, Cohn & Wolfe
Colombia: Giselle Díaz Bermúdez, SPR Group
This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, “expects”, “is expected”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements include statements with respect to the expected yield of PharmaCielo’s high-THC cultivars, PharmaCielo’s intentions regarding the processing and sale of its high-THC cultivars and the anticipated timing of the harvest and processing of PharmaCielo’s high-THC cultivars. Forward-looking statements are based on assumptions, including with respect to PharmaCielo’s ability to execute its business plan as currently contemplated, that management believes are reasonable in the circumstances, but the actual results, performance or achievements of PharmaCielo’s business may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, risks inherent in agricultural businesses, competition for PharmaCielo’s planned products, risks associated with operating in Colombia, currency exchange risk and those factors discussed or referred to under the heading “Risk Factors” in PharmaCielo’s Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com . Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.